{"id":"azd8529","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3937907","moleculeType":"Small molecule","molecularWeight":"487.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD8529 works by blocking the action of adenosine at the A2A receptor, which is involved in the regulation of inflammation and immune responses. This blockade is thought to have anti-inflammatory effects and may help to reduce the severity of certain diseases.","oneSentence":"AZD8529 is a selective adenosine A2A receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:24.891Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT02401022","phase":"PHASE2","title":"The Study of AZD8529 for Smoking Cessation in Female Smokers","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2015-07","conditions":"Tobacco Use Disorder","enrollment":214},{"nctId":"NCT00986531","phase":"PHASE1","title":"The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Schizophrenia","enrollment":59},{"nctId":"NCT00985933","phase":"EARLY_PHASE1","title":"The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Healthy, Memory Impairment","enrollment":20},{"nctId":"NCT00921804","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT00886756","phase":"PHASE1","title":"AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Healthy","enrollment":48},{"nctId":"NCT00765492","phase":"PHASE1","title":"AZD8529 Multiple Ascending Dose Study in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Healthy Volunteer","enrollment":47},{"nctId":"NCT00755378","phase":"PHASE1","title":"AZD8529 Single Ascending Dose Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Healthy Volunteer","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD-8529"],"phase":"phase_2","status":"active","brandName":"AZD8529","genericName":"AZD8529","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD8529 is a selective adenosine A2A receptor antagonist. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}